Before Investing in Organon & Co., Read This Report!

Shares of Organon & Co. have moved -5.6% today, and are now trading at a price of $19.83. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 3,164,356 compared to the stock's average volume of 1,994,391.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Based in Jersey City, United States the company has 10,000 full time employees and a market cap of $5,067,913,216. Organon & Co. currently offers its equity investors a dividend that yields 5.3% per year.

The company is now trading -36.03% away from its average analyst target price of $31.0 per share. The 6 analysts following the stock have set target prices ranging from $23.0 to $43.0, and on average give Organon & Co. a rating of hold.

Over the last 12 months OGN shares have declined by -30.0%, which represents a difference of -44.0% when compared to the S&P 500. The stock's 52 week high is $32.43 per share and its 52 week low is $18.87. With its net margins declining an average -15.9% over the last 2 years, Organon & Co. declining profitability gives us reason to believe its stock price will continue to underwhelm.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023-02-27 6,174,000 917,000 15 -28.57
2022-03-21 6,304,000 1,351,000 21
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.